Altogether, this suggests that AML patients with TP53 mutation could benefit from T‐cell modulatory therapy, and as PD‐1 therapy have shown limited effect in AML, other targets could potentially be better suited.5 The gene discussed is TP53; the disease is acute myeloid leukemia.